BerGenBio

Share Issue/Capital Change • Feb 18, 2019

BerGenBio ASA: Share capital increase

BerGenBio ASA: Share capital increase

Bergen, Norway, 18 February 2019 - Reference is made to the stock exchange notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 14 February 2019 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the exercise options pursuant to the Company's share option program. A total of 140,000 options were exercised at an average subscription price of NOK 10.62 per share.

The share capital increase has been duly registered in the Norwegian Register of Business Enterprises. Following such registration, the Company's share capital is NOK 5,485,144.60 divided into 54,851,446 shares, each with a nominal value of NOK 0.10.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.